GLOBAL PHARMA GIANTS TURN TO CHINESE BIOTECH TO TAP INNOVATION, VALUATION GROWTH
REPORT A PROBLEM WITH THIS SOURCE
SOURCE AGREEMENT & OPEN QUESTIONS
One linked publisher is currently carrying this report in the live cache.
WHAT REMAINS UNCLEAR
RSS excerpts are short and may omit qualifications, timing or attribution. Read the original reports before treating a detail as settled.
WHERE REPORTING MAY DIFFER
Independent comparison coverage has not yet been identified in the current live cache.
SOURCE COMPARISON
| Source | Latest linked headline | Age |
|---|---|---|
| News - South China Morning Post | GLOBAL PHARMA GIANTS TURN TO CHINESE BIOTECH TO TAP INNOVATION, VALUATION GROWTH | 2 hrs ago |
WHAT HAPPENED
Global pharmaceutical giants are shifting their business strategies in China, investing in the country's fast-growing biotech companies to tap into innovation and potential valuation growth. According to speakers at the Global Health Summit in Hong Kong, multinational companies are moving away from asset-heavy operations towards investing in local firms. This strategic move is expected to boost growth in China's biotech sector.
The healthcare group head at Citic Securities, Xu Chenming, stated that multinational pharmaceutical companies are altering their approach in China, focusing on investments rather than maintaining heavy assets. This change in strategy reflects the huge room for valuation growth in China's biotech sector. However, specific details on the scale of investments or the number of companies involved were not provided.
The development is significant as it highlights the growing importance of China's biotech industry, with global players seeking to capitalize on its innovation and growth potential. This move also underscores the evolving business landscape in China, with companies adapting to new opportunities and shifting away from traditional models.
- Global pharmaceutical giants are investing in China's biotech companies
- Multinational companies are shifting away from asset-heavy operations in China
- China's biotech sector has huge room for valuation growth
RELATED DAMMNEWS COVERAGE
- TYPHOON DOLPHIN GROUNDS HONG KONG FLIGHTS, DISRUPTS TRIPS AND BUSINESS IN JAPAN
News - South China Morning Post • 1 hr ago • CHINA - MANILA-BOUND FLIGHT RETURNS TO HONG KONG AFTER SUSPECTED CARGO DOOR ISSUE
News - South China Morning Post • 1 hr ago • CHINA - PRESIDENT XI NEVERS WASTES A GOOD CRISIS. AS IRAN, UKRAINE AND PALESTINE DISTRACT THE WORLD, HE TIGHTENS HIS GRIP | SIMON TISDALL
The Guardian • 1 hr ago • UK